Sign in

Jenny Rabinowitz

Global Investment Research Analyst at Goldman Sachs Group Inc.

Jenny Rabinowitz is a Global Investment Research Analyst at Goldman Sachs Group Inc., specializing in providing research and analysis across key companies and sectors for institutional investors. She is responsible for delivering in-depth coverage and investment recommendations, although specific company names and quantitative performance metrics such as returns or analyst rankings are not publicly available. Rabinowitz began her career at Goldman Sachs and has continued to advance within their investment research division; there is no evidence in public domains of prior experience at other firms. Her professional credentials and securities licenses, such as FINRA registration details, are not listed in accessible sources.

Jenny Rabinowitz's questions to STRYKER (SYK) leadership

Question · Q3 2025

Jenny Rabinowitz asked for details on the two smaller product acquisitions completed during the quarter, specifically about the products and markets, and if such smaller tuck-in acquisitions should be expected going forward.

Answer

Kevin Lobo (Chair and CEO, Stryker) confirmed that small tuck-in acquisitions are part of Stryker's strategy. He described the NP Seal product as a negative pressure wound treatment without capital equipment, fitting into the orthopaedic instrument sales reps' bag. The second acquisition, Advanced Medical Balloons, offers a fecal incontinence product for the Sage business, representing a new market for Stryker. He clarified that these are primarily about optimizing existing call points rather than a broader wound strategy.

Ask follow-up questions

Question · Q3 2025

Jenny Rabinowitz asked for more details on the two smaller product acquisitions made during the quarter (Guard Medical's NP Seal and Advanced Medical Balloons) and whether such smaller product acquisitions should be expected going forward.

Answer

Kevin Lobo, Chair and Chief Executive Officer, described Guard Medical's NP Seal as a capital-free negative pressure wound treatment that fits well into the Orthopaedic Instruments sales bag. He explained Advanced Medical Balloons addresses fecal incontinence, a new area for the Sage business. He confirmed that small, tuck-in acquisitions are a consistent part of Stryker's strategy.

Ask follow-up questions

Question · Q2 2025

Jenny Rabinowitz of Goldman Sachs asked about Stryker's strategy for international expansion, balancing organic versus inorganic investment, and for reflections on the SURF acquisition's impact on the European orthopedics business.

Answer

Chair & CEO Kevin Lobo stated the SURF acquisition has been very successful, boosting international hip performance, and that its products will soon launch in the US. He emphasized the biggest international opportunity is penetrating existing markets with Stryker's portfolio, including recent US acquisitions like Inari. He noted that growth has been hampered by slow EU MDR approvals for key products like Pangaea and Insignia, but expects international growth to re-accelerate in the second half of the year.

Ask follow-up questions

Jenny Rabinowitz's questions to Solventum (SOLV) leadership

Question · Q2 2025

Jenny Rabinowitz, on for David Roman, asked for the rationale behind raising organic sales and EPS guidance while maintaining the full-year free cash flow guidance.

Answer

CFO Wayde McMillan explained that while sales and earnings performance has been strong, free cash flow had a slower start to the year due to the timing of certain payments. The company is therefore maintaining the guidance as it has work to do in the second half to achieve the existing range, with improvements expected from working capital and lower deferred cash payments.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%